Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis.
Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis.
复制标题
DOI：
10.1093/schbul/sby032
复制
发表时间：
2018-08-20
影响因子：
6.6
通讯作者：
Haddock G
中科院分区：
文献类型：
--
作者：
Bucci S;Barrowclough C;Ainsworth J;Machin M;Morris R;Berry K;Emsley R;Lewis S;Edge D;Buchan I;Haddock G
及时获得精神病干预至关重要，但也存在问题。因此，医疗保健提供者正在制定应对心理健康挑战的数字战略。一种理论驱动的数字干预，监测痛苦的经历，并提供实时的积极管理策略，可以提高精神病康复的速度和质量，超过传统治疗。本研究评估了Actissists的可行性和可接受性，Actissists是一种基于精神病认知模型的数字健康干预措施，针对关键的早期精神病领域。一项概念验证、单盲、随机对照的Actisist试验，与监测对照组相比。36名早期精神病患者以2：1的比例随机分配到试验的每组。Actisist通过智能手机应用程序在12周内提供;临床和功能评估时间点为基线，治疗后和22周。评估者对治疗情况不知情，进行了评估。使用定性方法检查可接受性。Actissist是可行的（75%的参与者每天至少使用一次Actissist;吸收率高，97%的参与者留在试验中;随访率高），可接受的（90%的参与者推荐Actissist），安全的（0起严重不良事件），用户满意度高。治疗对阴性症状、一般精神病性症状和情绪的影响较大。增加Actissists在治疗后评估中的获益超过常规的血糖监测和常规治疗。这是第一次对早期精神病的理论驱动的数字健康干预进行对照概念验证试验。Actisist对早期精神病患者是可行和可接受的，具有强烈的治疗疗效信号。试验注册：ISRCTN：34966555。
Timely access to intervention for psychosis is crucial yet problematic. As such, health care providers are forming digital strategies for addressing mental health challenges. A theory-driven digital intervention that monitors distressing experiences and provides real-time active management strategies could improve the speed and quality of recovery in psychosis, over and above conventional treatments. This study assesses the feasibility and acceptability of Actissist, a digital health intervention grounded in the cognitive model of psychosis that targets key early psychosis domains. A proof-of-concept, single, blind, randomized controlled trial of Actissist, compared to a symptom-monitoring control. Thirty-six early psychosis patients were randomized on a 2:1 ratio to each arm of the trial. Actissist was delivered via a smartphone app over 12-weeks; clinical and functional assessment time-points were baseline, post-treatment and 22-weeks. Assessors’ blind to treatment condition conducted the assessments. Acceptability was examined using qualitative methods. Actissist was feasible (75% participants used Actissist at least once/day; uptake was high, 97% participants remained in the trial; high follow-up rates), acceptable (90% participants recommend Actissist), and safe (0 serious adverse events), with high levels of user satisfaction. Treatment effects were large on negative symptoms, general psychotic symptoms and mood. The addition of Actissist conferred benefit at post-treatment assessment over routine symptom-monitoring and treatment as usual. This is the first controlled proof-of-concept trial of a theory-driven digital health intervention for early psychosis. Actissist is feasible and acceptable to early psychosis patients, with a strong signal for treatment efficacy. Trial Registration: ISRCTN: 34966555.
登录
查看更多内容
影响因子：
2.5
作者：
Bucci S;Barrowclough C;Ainsworth J;Morris R;Berry K;Machin M;Emsley R;Lewis S;Edge D;Buchan I;Haddock G
通讯作者：
Haddock G
影响因子：
4.5
作者：
ADDINGTON, D;ADDINGTON, J;SCHISSEL, B
通讯作者：
SCHISSEL, B
影响因子：
6.6
作者：
Firth, Joseph;Cotter, Jack;Yung, Alison R.
通讯作者：
Yung, Alison R.
DOI：
10.1136/bmj.c6325
发表时间：
2010-11-24
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Barrowclough C;Haddock G;Wykes T;Beardmore R;Conrod P;Craig T;Davies L;Dunn G;Eisner E;Lewis S;Moring J;Steel C;Tarrier N
通讯作者：
Tarrier N
影响因子：
73.3
作者：
Firth, Joseph;Torous, John;Sarris, Jerome
通讯作者：
Sarris, Jerome